Libra Infusions (DHA:LIBRAINFU) EBITDA Margin %: 0.00% (As of . 20)


DHA:LIBRAINFU Libra Infusions Ltd DHA:LIBRAINFU
20 GF Score
Price BDT642.40
View Full Analysis

What is Libra Infusions EBITDA Margin %?

Libra Infusions DHA:LIBRAINFU +0.45% 20 EBITDA Margin % is 0.00% as of . 20. GuruFocus rates DHA:LIBRAINFU with a GF Score™ of 20/100. Among 816 Medical Devices & Instruments companies, Libra Infusions ranks worse than 122548.9% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Libra Infusions's EBITDA for the six months ended in . 20 was BDT0.00 Mil. Libra Infusions's Revenue for the six months ended in . 20 was BDT0.00 Mil. Therefore, Libra Infusions's EBITDA margin for the quarter that ended in . 20 was 0.00%.

Libra Infusions  (DHA:LIBRAINFU) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Libra Infusions EBITDA Margin % Related Terms

Libra Infusions EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Libra Infusions's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Libra Infusions EBITDA Margin % Chart

Libra Infusions Annual Data
Trend
EBITDA Margin %

Libra Infusions Semi-Annual Data
EBITDA Margin %

DHA:LIBRAINFU vs SECI, LENSF, ASNB: EBITDA Margin % Comparison

For the Medical Instruments & Supplies subindustry, Libra Infusions's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Libra Infusions EBITDA Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Libra Infusions's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Libra Infusions's EBITDA Margin % falls into.


DHA:LIBRAINFU
20GF Score
Libra Infusions Ltd DHA:LIBRAINFU
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Libra Infusions EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Libra Infusions's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

Libra Infusions's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Libra Infusions (DHA:LIBRAINFU) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Libra Infusions and its competitors. According to the industry distribution chart, Libra Infusions ranks #999999 out of 816 companies in the Medical Devices & Instruments industry.
Is Libra Infusions' EBITDA Margin % too high?
Libra Infusions' current EBITDA Margin % is 0.00%. Based on the distribution chart, Libra Infusions ranks #999999 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Libra Infusions has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Libra Infusions' EBITDA Margin % compare to SECI and LENSF?
According to the Medical Devices & Instruments industry distribution chart, Libra Infusions ranks #999999 out of 816 companies for EBITDA Margin %. This places Libra Infusions in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Libra Infusions and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Libra Infusions's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Libra Infusions stock overvalued right now?
Libra Infusions (DHA:LIBRAINFU) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Libra Infusions' overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Libra Infusions (DHA:LIBRAINFU), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Libra Infusions Business Description

Address I/7, Mirpur Industrial Estate, Rupnagar, Section-2, Dhaka, BGD, 1216
Libra Infusions Ltd is engaged in manufacturing intravenous fluids. It provides products which are used for medical purposes involving surgical operations, loss of blood, weakness, and general hospitalization.
20GF Score

Get the complete analysis for DHA:LIBRAINFU

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT642.40
Price